anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a compound tablet containing a kelp extract and cordyceps militaris. The compound tablet comprises the following components in percentage by weight: 10-45% of the kelp extract, 10-45% of cordyceps militaris and 5-30% of an additive. A method for preparing the compound tablet containing kelp extract and cordyceps militaris comprises the following steps: (1) preparing the kelp extract; (2) adding cordyceps militaris into the kelp extract prepared in the step (1); and (3) adding the additive and tabletting a compound sugar-tablet. By extracting polysaccharide substances from kelp, the cordyceps militaris is added to form complex carbohydrate, so that the compound tablet has better treatment effect on diabetes and nephropathy then medicine only containing kelp extract or the cordyceps militaris. Based on effectively exerting the effect of two natural polysaccharides of algal polysaccharide and the cordyceps militaris, the compound tablet is formed through full and accurate experiments. The effect of the compound tablet is remarkably better than that of single prescription of the algal polysaccharide and the cordyceps militaris.
The persistence of coronavirus disease 2019 (COVID-19)-related hospitalization severely threatens medical systems worldwide and has increased the need for reliable detection of acute status and prediction of mortality. We applied a systems biology approach to discover acute-stage biomarkers that could predict mortality. A total 247 plasma samples were collected from 103 COVID-19 (52 surviving COVID-19 patients and 51 COVID-19 patients with mortality), 51 patients with other infectious diseases (IDCs) and 41 healthy controls (HCs). Paired plasma samples were obtained from survival COVID-19 patients within 1 day after hospital admission and 1-3 days before discharge. There were clear differences between COVID-19 patients and controls, as well as substantial differences between the acute and recovery phases of COVID-19. Samples from patients in the acute phase showed suppressed immunity and decreased steroid hormone biosynthesis, as well as elevated inflammation and proteasome activation. These findings were validated by enzyme-linked immunosorbent assays and metabolomic analyses in a larger cohort. Moreover, excessive proteasome activity was a prominent signature in the acute phase among patients with mortality, indicating that it may be a key cause of poor prognosis. Based on these features, we constructed a machine learning panel, including four proteins [C-reactive protein (CRP), proteasome subunit alpha type (PSMA)1, PSMA7, and proteasome subunit beta type (PSMB)1)] and one metabolite (urocortisone), to predict mortality among COVID-19 patients (area under the receiver operating characteristic curve: 0.976) on the first day of hospitalization. Our systematic analysis provides a novel method for the early prediction of mortality in hospitalized COVID-19 patients.
1322019 Tetracycline-sulphonamide drug antibiotics M G ROUCHY 1 July 1970 [1 July 1969] 31844/70 Heading C2A The invention comprises an antibiotic of the tetracycline type linked to a sulphonamide drug through the 2-carboxamido function of the tetracycline nucleus by means of a group derived from an aldehyde. The antibiotic has the formula wherein R 0  is the hydronaphthalene skeleton of an antibiotic of the tetracycline type; R 1  is a solubilizing group of formula A-SO 3 -B, A-COOB, A-SO 3 H or A-COOH wherein A is a hydrocarbon radical, B is an alkali metal, alkaline earth metal or organic base and the solubilizing group is attached to the tetracycline nucleus via replaceable OH groups or the N in the 4-position of the nucleus; n is 0, 1, 2, 3 or 4, depending upon the number of replaceable OH groups on the tetracycline nucleus R 0 ; R 2  is the residue of an aldehyde (including H); R 3  is the residue of a sulphonamide drug following removal of an amino or alkyl amino group, the sulphonamide residue optionally containing a solubilizing group attached to the N atom; R 4  is H or C 1 -C 6  alkyl. R 1  may be a propane sulphonate, an ortho benzyl sulphonate or an ethane carboxylate. The tetracyclines are produced by reacting a tetracycline antibiotic with a sulphonamide and the aldehyde in the presence of a solvent. Alternatively, a tetracycline already methylene-substituted at the 2- carboxamide position by a radical which can be displaced by sulphonamide may be used as starting material. Examples relate to sodium tetracycline methylene sulphamethoxy-pyridazine-N-1-propane sulphonate, sodium chlorotetracycline methylene sulphamethoxazole-N- ethane carboxylate, sodium tetracycline methylene - 2 - sulphanilamido - 5 - methoxy pyrimidine-N-propane sulphonate, sodium tetracycline methylene sulphamethoxypyridazine, tetracycline methylene - 1 - carboxylic acid sulphadimethoxime and the corresponding chlorotetracycline, tetracycline sulphamethoxypyridazine-N-propane sulphonate and others. Salts may be formed with physiologically acceptable acids or bases, e.g. penicillins, cephalosporins, neomycin, streptomycin, dihydrostreptomycin, kanamycin and erythromycin. Pharmaceutical compositions comprise as an essential ingredient thereof at least one tetracycline type antibiotic linked with a sulphonamide drug as defined above.
Impaired Liver Function

Do not use Mono-Linyah in women with liver disease, such as acute viral hepatitis or severe (decompensated) cirrhosis of liver [see Contraindications (4)]. Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal and COC causation has been excluded. Discontinue Mono-Linyah if jaundice develops.

Liver Tumors

Mono-Linyah is contraindicated in women with benign and malignant liver tumors [see Contraindications (4)]. Hepatic adenomas are associated with COC use. An estimate of the attributable risk is 3.3 cases/100,000 COC users. Rupture of hepatic adenomas may cause death through intra-abdominal hemorrhage.

Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (>8 years) COC users. However, the risk of liver cancers in COC users is less than one case per million users.
PCT No. PCT/CU97/00001 Sec. 371 Date Sep. 16, 1997 Sec. 102(e) Date Sep. 16, 1997 PCT Filed Jan. 17, 1997 PCT Pub. No. WO97/26359 PCT Pub. Date Jul. 24, 1997The present invention relates to biotechnology and genetic engineering, particularly the expression of proteins of viral origin in microorganisms through their fusion, by applying the recombinant DNA technology, to bacterial peptides. The present invention provides an efficient process for the expression in Escherichia coli of heterologous proteins as fusion polypeptides with a view to obtaining them with a high degree of purity, in commercially useful amounts, and in an appropriate form for their inclusion in vaccine preparations intended to human use. To this effect, what is essentially used is a stabilizing sequence derived from the first 47 amino acids of the antigen P64k of Neisseria meningitidis B:4:P1.15. In particular, use is made of a recombinant plasmid containing said sequence, under the control of the tryptophane promotor of E. coli and of the terminator of the transcription of the phage T4, including restriction sites which provide for the cloning in phase of DNA fragments coding for polypeptides of interest. The process of the invention is applicable to the pharmaceutical industry, for the development of diagnostic systems, vaccine preparations, and in any situation where it is required to obtain high amounts of heterologous proteins as fusion polypeptides in E. coli.
BACKGROUND: Thromboembolic events, including myocardial infarction (MI) or stroke, caused by the rupture or erosion of unstable atherosclerotic plaques are the leading cause of death worldwide. Although most mouse models of atherosclerosis develop lesions in the aorta and carotid arteries, they do not develop advanced coronary artery lesions. Moreover, they do not undergo spontaneous plaque rupture with MI and stroke or do so at such a low frequency that they are not viable experimental models to study late-stage thrombotic events or to identify novel therapeutic approaches for treating atherosclerotic disease. This has stymied the development of more effective therapeutic approaches for reducing these events beyond what has been achieved with aggressive lipid lowering. Here, we describe a diet-inducible mouse model that develops widespread advanced atherosclerosis in coronary, brachiocephalic, and carotid arteries with plaque rupture, MI, and stroke.
METHODS: We characterized a novel mouse model with a C-terminal mutation in the scavenger receptor class B, type 1 (SR-BI), combined with Ldlr knockout (designated SR-BI∆CT/∆CT/Ldlr-/-). Mice were fed Western diet (WD) for 26 weeks and analyzed for MI and stroke. Coronary, brachiocephalic, and carotid arteries were analyzed for atherosclerotic lesions and indices of plaque stability. To validate the utility of this model, SR-BI∆CT/∆CT/Ldlr-/- mice were treated with the drug candidate AZM198, which inhibits myeloperoxidase, an enzyme produced by activated neutrophils that predicts rupture of human atherosclerotic lesions.
RESULTS: SR-BI∆CT/∆CT/Ldlr-/- mice show high (>80%) mortality rates after 26 weeks of WD feeding because of major adverse cardiovascular events, including spontaneous plaque rupture with MI and stroke. Moreover, WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice displayed elevated circulating high-sensitivity cardiac troponin I and increased neutrophil extracellular trap formation within lesions compared with control mice. Treatment of WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice with AZM198 showed remarkable benefits, including >90% improvement in survival and >60% decrease in the incidence of plaque rupture, MI, and stroke, in conjunction with decreased circulating high-sensitivity cardiac troponin I and reduced neutrophil extracellular trap formation within lesions.
CONCLUSIONS: WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice more closely replicate late-stage clinical events of advanced human atherosclerotic disease than previous models and can be used to identify and test potential new therapeutic agents to prevent major adverse cardiac events.
The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
Patients will recruite among those attending the Clinic of Tashkent Medical Academy, Uzbekistan. Three groups of headache patients will be enrolled in this prospective study: patients with episodic migraine with and without aura, episodic cluster headache, and frequent episodic tension-type headache according to the current criteria of the International Headache Society. In migraineurs, venous blood samples will be collected twice: outside and during migraine attacks prior to pain medication. In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF will performed using enzyme-linked immunosorbent assay technique. In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take.Patients with a history of cardiovascular disease, major depression, hypertension, drug or alcohol abuse, or other apparent diseases will be excluded from the study. The research will comprise 120 patients (males and females) suffering from primary headache. At the moment we started collecting patients.
After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
The invention provides an in-vehicle device, a first information processing device, an information processing system and an information processing method, which reduce the burden of doctors except for diagnosis and treatment. The second terminal device (15) has an input unit, a communication unit, and an output unit. The input unit detects a user input for specifying a relative position on a living body to be examined. The communication unit transmits the relative position to the first information processing apparatus. The communication unit receives at least one of the first sound and the first subject image from the first information processing device (12). The output unit outputs at least one of the first sound and the first subject image.
Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
NULIBRY must be reconstituted prior to use. Use aseptic technique during preparation and follow these instructions: 

  1. Determine the total dose, number of vials needed, and total reconstituted dose volume based on the patient's weight and prescribed dose. 
  2. Remove the required number of vials from the freezer to allow them to reach room temperature (by hand warming for 3 to 5 minutes or exposing to ambient air for approximately 30 minutes). 
  3. Reconstitute each required NULIBRY vial with 5 mL of Sterile Water for Injection, USP. Gently swirl the vial continuously until the powder is completely dissolved. DO NOT shake. After reconstitution, the final concentration of NULIBRY reconstituted solution is 9.5 mg/5 mL (1.9 mg/mL). 
  4. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstituted NULIBRY is a clear and colorless to pale yellow solution. Do not use if there are particles present or if the solution is discolored. 
  5. Administer the total reconstituted dose.
Venous thrombo-embolic disease (VTED) is a frequent pathology. The incidence is about 5 to 20 cases for 10000 persons each year, in a general population. The immediate risk is the pulmonary embolism potentially fatal. So, it justifies all the works in clinical research during the last years. Those studies allow many progresses, diagnostic and therapeutic, for the immediate undertaking of the patients. Despite that, VTED is a major problem of public health and the diminution of the mortality lied to VTED is one of the objectives of the French law relative to the politics of Public Health (August 2004). At more long-term, the post-thrombotic syndrome lead to an incapacitating pathology, which requires many cares. The frequency of the post-thrombotic syndrome is evaluated between 25 and 60% at middle-term (1 or 2 years). It depends of the studies and of the clinical primary end-points or vascular explorations. Rehabilitation has never been validated in this indication by studies with a correct methodology.

Deep venous thrombosis (not in acute phase) is recognized as an indication for about 10 spa in France. But the specific or global benefit of this water cure is not clearly and scientifically proved. The importance of the venous pump of the calf and of the hydrostatic pressure in the physiopathology of the post-thrombotic syndrome make natural the use of balneotherapy for the prevention of this pathology for patients with severe deep venous thrombosis of lower limbs (proximal and obstruent). The venous thermal techniques have well-defined physiopathological targets. The haemodynamic and microcirculatory effects of some of them have been proved. The high degree of satisfaction of the patients that benefit from phlebological water cure every year in France indirectly shows the benefits that they feel. In those indications, prevention of the post-thrombotic syndrome is one of the well-recognize by the medical profession. For all that, there was not really validation of this indication with an acceptable methodology for the canons of the modern medicine. That is the reason why we undertake this randomized, single-blind controlled study with for main objective to demonstrate that hydrotherapy in a specific place can reduce the risk of post-thrombotic syndrome.
Standard WHO-ORS. Initial treatment dosing with WHO-ORS will be estimated using body weight in accordance with 5-10 ml/kg after each loose stool as per icddr,b guidelines, to maintain ongoing loss.
The invention belongs to the technical field of Chinese herbal medicines, and discloses a traditional Chinese medicine compound composition for treating ischemic stroke and a preparation method thereof. The composition is composed of 7 traditional Chinese medicines, and aims at wind, fire, phlegm and blood stasis of pathological factors in the acute stage of apoplexy. In the formula, the root of red-rooted salvia has the functions of promoting blood circulation to remove blood stasis and eliminating blood stasis toxin; the big Huang Tongfu purgation can clear heat and remove stasis, and can clear fire and remove toxin of stasis; fructus Trichosanthis has effects of dredging viscera, eliminating phlegm, and promoting the function of Huang Tongfu, and can clear phlegm-heat toxin; the three medicines are used together for clearing heat and detoxicating, dredging viscera and eliminating phlegm, promoting blood circulation and removing blood stasis, and eliminating phlegm, heat and blood stasis. Gardenia has the effects of clearing heat and purging fire, and can help to increase Huang Hangqing heat and clear toxic heat; gastrodia elata has the effects of calming liver to stop wind and eliminating pathogenic wind in the liver; rhizoma Acori Graminei has effects of inducing resuscitation, eliminating phlegm, activating the Xuanfu, and clearing phlegm toxin; dan nan xing has the actions of clearing fire and resolving phlegm, clearing phlegm-heat and resolving toxin, and Gua Lou has the actions of clearing heat and resolving phlegm. The whole prescription aims at wind-fire phlegm stasis in the acute stage of apoplexy, and has the effects of clearing heat and detoxicating, eliminating phlegm and inducing resuscitation, and activating blood circulation and removing obstruction in collaterals. Experiments show that the composition also has the brain protection effects of inhibiting inflammation and resisting apoptosis.
The present invention relates to the treatment of infections due to antibiotic-resistant bacteria. Antimicrobial resistance (AMR) has been observed at dangerously high levels worldwide and alternative strategies are urgently needed. Antisense therapy has been identified as potential therapeutic tool for tackling AMR. However, in the context of AMR, since the antisense oligonucleotides have to reach the target mRNA to be efficient, the cellular uptake inside prokaryotic cells is a critical issue. The inventors demonstrated that antisense oligonucleotide sequences, in particular targeting the bla CTX/M15 gene, featuring a lipid moiety conjugated to the ASO extremity show a particularly efficient intracellular penetration in prokaryotic cells and that these lipid-modified antisense oligonucleotides can show a further improved enzymatic stability with phosphorothioate chemistry (PTO). In particular, the present invention relates to an antisense oligonucleotide modified by substitution at the 5' or the 3' end by a lipid moiety, wherein said antisense oligonucleotide specifically targets an mRNA encoding a CTX-M extended spectrum β-lactamase. Another object of the invention concerns the antisense oligonucleotide of the invention for use for treating a bacterial infection, in particular due to bacteria resistant to 3rd generation cephalosporins.
Acinetobacter baumannii is a globally distributed opportunistic pathogen in human health settings, including in intensive care units (ICUs). We investigated the contamination of a French small animal ICU with A. baumannii. We discovered repeated animal contamination by A. baumannii, and phylogenetic analysis traced contamination back to a potential foreign animal origin. Genomic analysis combined with antibiotic susceptibility testing revealed heteroresistance to penicillin and aminoglycoside mediated by insertion sequence dynamics and also suggest a potential cross-resistance to human-restricted piperacillin-tazobactam combination. The A. baumannii isolates of the animal ICU belong to the International Clone 2 commonly found in human health settings. Our results suggest a high adaptation of this lineage to healthcare settings and provide questions on the requirements for genetic determinants enabling adaptation to host and abiotic conditions.
OBJECTIVE: To evaluate the safety and efficacy of percutaneous transhepatic endoscopic holmium laser lithotripsy (PTEHL) for patients with intrahepatic bile duct (IHBD) and common bile duct (CBD) stones.
MATERIAL AND METHODS: This retrospective study included 530 patients (mean age: 55.6 ± 8.5; 64.2% female) with IHBD and/or CBD stones at a single institution from January 2019 to December 2021. PTEHL was the chosen treatment for patients with large, complex stones, or those for whom Endoscopic Retrograde Cholangiopancreatography (ERCP) failed or presented difficulties. Patients showing signs of cholangitis required pre-PTEHL drainage. Stone clearance was confirmed by post-procedural cholangiography, and the technique was deemed successful when target stones were removed. Complications were recorded according to the Society of Interventional Radiology adverse event classification.
RESULTS: The mean stone size was 20.9 ± 11.9 mm, multiple stones observed in 460 patients (86.8%). A total of 225 patients (42.5%) had stones in both the IHBD and CBD; biliary-enteric anastomosis in 50 patients (9.4%). ERCP for stone removal proved unsuccessful in 18 patients (3.4%). Pre-IHBD drainage was performed in 271 patients (51.1%). The majority (488 patients, 92.1%) underwent a single PTEHL session. The technique was successful in 523 patients (98.7%), with 7 patients requiring surgery due to unsuccessful target stone removal. Complications were noted in 75 patients (14.2%), including 4.7% with severe complications and 9.4% with minor complications.
CONCLUSION: PTEHL is a safe and effective method for the treatment of both intrahepatic and extrahepatic bile duct stones. This approach is a valuable option for complex stone cases, particularly when ERCP is unsuccessful or encounters significant challenges.
CLINICAL RELEVANCE STATEMENT: Percutaneous Transhepatic Endoscopic Holmium Laser Lithotripsy is a safe and effective treatment method for intrahepatic and extrahepatic biliary stones, particularly in cases of complex stones.
KEY POINTS: Percutaneous transhepatic biliary stone removal is difficult for large or intraductal stones. Percutaneous Transhepatic Endoscopic Holmium Laser Lithotripsy (PTEHL) demonstrated a high success rate with few major complications. PTEHL can treat biliary stones, particularly stones that are difficult or have failed ERCP treatment.
Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.